Hygromycin is under clinical development by Flightpath BioSciences and currently in Phase I for Lyme Disease. According to GlobalData, Phase I drugs for Lyme Disease have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Hygromycin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hygromycin overview
Hygromycin (FP-100) is under development for the treatment of acute lyme borreliosis, endemic treponematoses, colorectal cancer and Weil's disease. It is administered through oral route. It acts by targeting bacterial ribosomal peptidyl transferase.
It was also under treatment for periodontal disease and congenital syphilis.
Flightpath BioSciences overview
Flightpath BioSciences is a developer of antibiotic therapies designed to treat pathogen-driven diseases. It kills infectious bacteria in lyme disease and offers antibiotic therapies to reduce the negative impact on the microbiome. The company is headquartered in Berkeley, California, the US.
For a complete picture of Hygromycin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
